Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer

Go back to Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
MACROGENICS (NASDAQ: MGNX) Delayed: 4.14 --0 (-0%)
Previous Close $4.14    52 Week High $36.11 
Open $4.14    52 Week Low $14.84 
Day High $4.14    P/E 10.62 
Day Low $4.14    EPS $0.39 
Volume 4,982       

(NASDAQ: ZLAB) Delayed: 25.70 --0 (-0%)
Previous Close $25.70    52 Week High
Open $25.70    52 Week Low
Day High $25.70    P/E N/A 
Day Low $25.70    EPS
Volume 42,468